Is NCT04508790 recruiting in Lancaster, CA?

Yes, NCT04508790 is currently recruiting participants at its Lancaster, CA location. This recurrent plasma cell myeloma clinical trial is actively enrolling qualified participants.

How do I join the recurrent plasma cell myeloma clinical trial in Lancaster?

To join this clinical trial in Lancaster, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Lancaster clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Recurrent Plasma Cell Myeloma Clinical Trial in Lancaster, CA

About This Recurrent Plasma Cell Myeloma Study in Lancaster

This phase II trial studies how well leflunomide, pomalidomide, and dexamethasone work for the treatment of multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Leflunomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with pomalidomide, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving leflunomide with pomalidomide and dexamethasone may work better in treating multiple myeloma compared to pomalidomide and dexamethasone alone.

Sponsor: City of Hope Medical Center

Who Can Participate

Inclusion Criteria

Documented informed consent of the participant and/or legally authorized representative

Assent, when appropriate, will be obtained per institutional guidelines

Agreement to allow the use of archival tissue from diagnostic tumor biopsies

If unavailable, exceptions may be granted with study principal investigator (PI) approval

Eastern Cooperative Oncology Group (ECOG) =\< 2

Life expectancy \> 3 months

Diagnosis of multiple myeloma with measurable disease as defined by:

M-protein quantities \>= 0.5 g/dL by serum protein electrophoresis (sPEP) or

\>= 200 mg/24 hour urine collection by urine protein electrophoresis (uPEP) or

Serum free light chain (FLC) \> 10.0 mg/dL involved light chain and an abnormal kappa/lambda ration in subjects without detectable serum or urine M-protein or

For subjects with immunoglobulin class A (IgA) myeloma whose disease can only be reliably measured by quantitative immunoglobulin measurement, a serum IgA level \>= 0.50 g/dL

Relapsed or refractory to at least 1 prior line of therapy, including both a proteasome inhibitor and an immunomodulatory drug, and for whom transplant is not recommended. Participants may opt for a delayed transplant at a later time, if appropriate

Fully recovered from the acute toxic effects (except alopecia) to =\< grade 2 to prior anti-cancer therapy

Absolute neutrophil count (ANC) \>= 1.0 x 10\^9/L (performed within 30 days prior to day 1 of protocol therapy unless otherwise stated)

NOTE: Screening ANC should be independent of granulocyte- and granulocyte/macrophage colony stimulating factor (G-CSF and GM-CSF) support for at least 1 week and of pegylated G-CSF for at least 2 weeks

Platelets \>= 75.0 x 10\^9/L (performed within 30 days prior to day 1 of protocol therapy unless otherwise stated)

NOTE: Screening platelet count should be independent of platelet transfusions for at least 2 weeks

Hemoglobin \>= 8.0 g/dL (performed within 30 days prior to day 1 of protocol therapy unless otherwise stated)

NOTE: Transfusion support is allowed

Total bilirubin =\< 2 X upper limit of normal (ULN) (unless has Gilbert's disease) (performed within 30 days prior to day 1 of protocol therapy unless otherwise stated)

Aspartate aminotransferase (AST) =\< 3.5 x ULN (performed within 30 days prior to day 1 of protocol therapy unless otherwise stated)

Alanine aminotransferase (ALT) =\< 3.5 x ULN (performed within 30 days prior to day 1 of protocol therapy unless otherwise stated)

Alkaline phosphatase \< 5 x ULN (performed within 30 days prior to day 1 of protocol therapy unless otherwise stated)

Creatinine clearance of \>= 30 mL/min per 24 hour urine test (performed within 30 days prior to day 1 of protocol therapy unless otherwise stated)

Women of childbearing potential (WOCBP): negative urine or serum pregnancy test

If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required

Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 4 weeks after the last dose of protocol therapy

Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \> 1 year (women only)

Exclusion Criteria

Prior treatment with leflunomide

Patients who are pomalidomide refractory, defined as subjects who progress on or within 60 days of pomalidomide when given as a single agent or in combinatorial therapies. Prior exposure to pomalidomide without refractoriness is allowed

Current or planned use of other anti-myeloma therapies besides leflunomide, pomalidomide, and dexamethasone

Current or planned growth factor or transfusion support until after initiation of treatment

Prior allogeneic transplant

History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agents

Positive for tuberculosis or latent tuberculosis (TB)

Positive for hepatitis A, B, or C

Known human immunodeficiency virus (HIV) infection

Prior diagnosis of rheumatoid arthritis

Acute active infection requiring systemic therapy within 2 weeks prior to enrollment

Subject has history of anaphylaxis to thalidomide, lenalidomide, pomalidomide, cholestyramine or dexamethasone

Non-hematologic malignancies within the past 3 years, with the exceptions of

Adequately treated basal cell or squamous cell skin cancer,

Carcinoma in situ of the cervix,

Prostate cancer \< Gleason grade 6 with stable prostate specific antigen (PSA), or

Successfully treated in situ carcinoma of the breast

Females only: Pregnant or breastfeeding

Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures

Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Lancaster?

Yes, this clinical trial (NCT04508790) has an active research site in Lancaster, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Recurrent Plasma Cell Myeloma Treatment Options in Lancaster, CA

If you're searching for recurrent plasma cell myeloma treatment options in Lancaster, CA, this clinical trial (NCT04508790) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Lancaster research site is actively enrolling participants for this clinical trial. You'll receive care from experienced recurrent plasma cell myeloma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all recurrent plasma cell myeloma clinical trials near you to find additional studies recruiting in your area.

Recurrent Plasma Cell Myeloma Clinical Trial in Lancaster, CA

Expert Care in Lancaster

IRB Approved

No-Cost Care

Apply for This Lancaster Location

Why Participate?

Simple Process